GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

atezolizumab   Click here for help

GtoPdb Ligand ID: 7990

Synonyms: MPDL3280A | Tecentriq®
Approved drug Immunopharmacology Ligand
atezolizumab is an approved drug (FDA (2016), EMA (2017))
Compound class: Antibody
Comment: Atezolizumab (MPDL3280A) is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence analysis using the light chain variable region of atezolizumab provides a 100% match to sequence 21 from patent US8217149. An X-ray crystal structure of the PD-L1/atezolizumab complex has been submitted to the RCSB PDB (accession 5X8L) [6].
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes. EU EMA (2017)  |  US FDA (2016)
International Nonproprietary Names Click here for help
INN number INN
9814 atezolizumab
Synonyms Click here for help
MPDL3280A | Tecentriq®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 526
Other databases
GtoPdb PubChem SID 249565671
Search PubMed clinical trials atezolizumab
Search PubMed titles atezolizumab
Search PubMed titles/abstracts atezolizumab
Wikipedia Atezolizumab